Paper8533995
An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group.
Ann Intern Med, 1996. Cited by 132 papers, by iCite.
Cite this record
ConductScience Library. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Papers, record 8533995. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8533995
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group.
- PubMed
- Publication types
- Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminosalicylic Acids | Major topic |
| Anti-Inflammatory Agents, Non-Steroidal | Major topic |
| Colitis, Ulcerative | Major topic |
| Adult | |
| Double-Blind Method | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Hydrogen-Ion Concentration | |
| Intestinal Absorption | |
| Male | |
| Mesalamine | |
| Patient Compliance | |
| Polymers | |
| Remission Induction | |
| Sulfasalazine | |
| Tablets, Enteric-Coated | |
| Time Factors | |
| Treatment Outcome |
Source PubMed
Cited by36
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 132 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41567252 | Long-Term Efficacy and Safety of Multi-Matrix Mesalazine Maintenance Therapy in Pediatric Patients with Ulcerative Colitis. | Pediatr Gastroenterol Hepatol Nutr | 2026 | https://conductscience.org/library/papers/41567252 | PubMed |
| 40955556 | Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5-Aminosalicylate for Ulcerative Colitis-The EASI Trial. | Aliment Pharmacol Ther | 2025 | https://conductscience.org/library/papers/40955556 | PubMed |
| 39990515 | A practical approach to positioning therapies in ulcerative colitis. | J Can Assoc Gastroenterol | 2025 | https://conductscience.org/library/papers/39990515 | PubMed |
| 39129949 | Patient Preferences for Ulcerative Colitis Treatment in the Middle East Region: A Discrete-Choice Experiment. | Gastro Hep Adv | 2024 | https://conductscience.org/library/papers/39129949 | PubMed |
| 36375794 | De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease. | Gut Liver | 2023 | https://conductscience.org/library/papers/36375794 | PubMed |
| 34725785 | Optimal Placement of Colectomy in the Treatment of Ulcerative Colitis: a Markov Model Analysis. | J Gastrointest Surg | 2021 | https://conductscience.org/library/papers/34725785 | PubMed |
| 34511961 | Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis. | Clin Exp Gastroenterol | 2021 | https://conductscience.org/library/papers/34511961 | PubMed |
| 32856298 | Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. | Cochrane Database Syst Rev | 2020 | https://conductscience.org/library/papers/32856298 | PubMed |
| 30727712 | Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. | Intest Res | 2019 | https://conductscience.org/library/papers/30727712 | PubMed |
| 28886205 | Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. | Cochrane Database Syst Rev | 2017 | https://conductscience.org/library/papers/28886205 | PubMed |
| 28670233 | Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study. | Intest Res | 2017 | https://conductscience.org/library/papers/28670233 | PubMed |
| 28239313 | Second Korean guidelines for the management of ulcerative colitis. | Intest Res | 2017 | https://conductscience.org/library/papers/28239313 | PubMed |
| 27158764 | Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. | Cochrane Database Syst Rev | 2016 | https://conductscience.org/library/papers/27158764 | PubMed |
| 26269667 | Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. | World J Gastroenterol | 2015 | https://conductscience.org/library/papers/26269667 | PubMed |
| 26199624 | Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. | Gastroenterol Res Pract | 2015 | https://conductscience.org/library/papers/26199624 | PubMed |
| 24127239 | Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. | Patient | 2013 | https://conductscience.org/library/papers/24127239 | PubMed |
| 23363459 | Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. | BMC Gastroenterol | 2013 | https://conductscience.org/library/papers/23363459 | PubMed |
| 22720120 | Endoscopy in inflammatory bowel disease when and why. | World J Gastrointest Endosc | 2012 | https://conductscience.org/library/papers/22720120 | PubMed |
| 22390554 | Mesalamine in the treatment and maintenance of remission of ulcerative colitis. | Expert Rev Clin Pharmacol | 2012 | https://conductscience.org/library/papers/22390554 | PubMed |
| 21904481 | A new look at a mainstay ulcerative colitis therapy. | Gastroenterol Hepatol (N Y) | 2008 | https://conductscience.org/library/papers/21904481 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Authors
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8533995
GET https://conductscience.org/api/papers/v1/8533995/cited_by?page=2